Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17-Beta-Estradiol 1 mg, Drospirenone 2 mg /17-Beta-Estradiol 1 mg, Drospirenone 1 mg /17-Beta-Estradiol 1 mg) Combinations and 17-Beta-Estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension.

X
Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17-Beta-Estradiol 1 mg, Drospirenone 2 mg /17-Beta-Estradiol 1 mg, Drospirenone 1 mg /17-Beta-Estradiol 1 mg) Combinations and 17-Beta-Estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol/drospirenone (Primary)
  • Indications Vasomotor symptoms
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.
  • Most Recent Events

    • 03 Mar 2009 Actual patient numbers (1879) added as reported by ClinicalTrials.gov.
    • 03 Mar 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 08 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top